// App-Quantinova.ai

FRI0139 : FILGOTINIB PROVIDED RAPID AND SUSTAINED RELIEF OF PAIN AND FATIGUE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS: RESULTS FROM THE FINCH 2 STUDY

Researchers

Presenter

  • D. Walker

Principal Investigators

  • T. Takeuchi

  • B. Bartok

  • S. Rao

  • I. H. Lee

  • R. Besuyen

  • J. E. Gottenberg

  • M. C. Genovese

Medical Centers

  • Northumbria Healthcare Trust, North Shields, United Kingdom

  • Keio Univ. School of Medicine, Tokyo, Japan

  • Gilead Sciences, Inc., Foster City, CA, United States.

  • Galapagos, Nv, Leiden, The Netherlands

  • Strasbourg University, Strasbourg, France

  • Stanford University, Materials Science & Engineering, Stanford, United States of America

Locations

  • United Kingdom

  • Japan

  • United States

  • Netherlands

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT02873936

Sponsors

  • Gilead Sciences Inc

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved